Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
AY.82 (Delta)NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
A.30NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.36.35NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
AY.23.1 (Delta)NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.466.1NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
AY.132 (Delta)NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.160.17NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
BA.4.1.10NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
XBB.1.19NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
KF.2NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
CS.1NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
BA.2.83NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
BJ.1NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
XDGNUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
GA.4NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
KD.1NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
XCSNUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-18863US
GA.7.1NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
FL.15.1NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
BA.2.40NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
CR.2NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
KB.3NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
GK.11NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
CJ.1.3.2NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
XANNUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
BN.1.4.2NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
DV.1NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
BA.5.2.11NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
BA.2.53NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
BA.4.3NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
EU.1.1.2NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
CM.2.1NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
XBB.1.43NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
HU.1NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
JB.2NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.256NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.26NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.177.77NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.34NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.248NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.32NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.70NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.1.43NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.559NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.1.14NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.1.406NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.69NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
A.26NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
ER.1.1NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
CH.1.1.23NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used